Epileptic Encephalopathy

Neurology·MeSH: Epilepsy

12 drugs in development·5 companies·4 clinical trials

Drug Pipeline by Phase

Phase 3(8)

Drug	Company
0.5mg elsunersen	Praxis Precision Medicines, Inc. (PRAX)
1.0mg/kg/day PRAX-562	Praxis Precision Medicines, Inc. (PRAX)
1.5mg/kg/day PRAX-562	Praxis Precision Medicines, Inc. (PRAX)
1mg elsunersen	Praxis Precision Medicines, Inc. (PRAX)
Bexicaserin (LP352)	Longboard Pharmaceuticals, Inc. (LBPH)
Elsunersen	Praxis Precision Medicines, Inc. (PRAX)
LP352	Longboard Pharmaceuticals, Inc. (LBPH)
LP352, bexicaserin	Longboard Pharmaceuticals, Inc. (LBPH)

Phase 2(3)

Drug	Company
nbi-827104	NEUROCRINE BIOSCIENCES INC (NBIX)
nbi-921352	Xenon Pharmaceuticals Inc. (XENE)
nbi-921352	NEUROCRINE BIOSCIENCES INC (NBIX)

Phase 1/Phase 2(1)

Drug	Company
gene therapy	Gene Biotherapeutics, Inc. (CRXM)

BioSniper tracks 12 drugs in development for Epileptic Encephalopathy across 5 companies.

There are 4 clinical trials targeting Epileptic Encephalopathy tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.